



Press release  
October 8, 2020

## First day of trading in Curasight's shares and warrants at Spotlight Stock Market

**Today is the first day of trading in Curasight A/S ("Curasight") shares and warrants of series TO 1. Curasight's shares are traded under the ticker "CURAS" with ISIN DK0061295797 and Curasight's warrants of series TO 1 are traded under the ticker "CURAS TO 1" with ISIN DK0061408747.**

Ahead of the listing at Spotlight Stock Market, Curasight has conducted a successful IPO which has provided the company with approx. DKK 32.7 million (before issue costs) and approx. 1,700 new shareholders. The issue funds will primarily finance the completion of a therapeutic preclinical study in brain cancer and a clinical phase III image study in brain cancer with the objective to obtain FDA approval and commercialize the uTRACE® platform. The total number of shares in Curasight is 17,126,340 shares and the share capital amounts to DKK 856,317.00. In addition, there are a total of 2,835,000 warrants of series TO 1 issued. Each warrant of series TO 1 entitles the holder the right to subscribe for one (1) new share in Curasight at a subscription price of DKK 17.20 per share during the exercise period September 16, 2021 until October 7, 2021.

### **Financial advisor and legal advisor**

Sedermera Fondkommission is the financial advisor of Curasight in connection with the capitalization and listing. Markets & Corporate Law is the legal advisor.

### **For additional information regarding the capitalization, please contact:**

Sedermera Fondkommission  
Phone: +46 (0) 40-615 14 10  
E-mail: [info@sedermera.se](mailto:info@sedermera.se)  
[www.sedermera.se](http://www.sedermera.se)

### **For more information regarding Curasight, please contact:**

Ulrich Krasilnikoff, CEO  
Phone: +45 22 83 01 60  
E-mail: [uk@curasight.com](mailto:uk@curasight.com)  
[www.curasight.com](http://www.curasight.com)

---

**Curasight** is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology provides improved diagnosis and risk stratification in multiple cancer types.